Moderna (NASDAQ:MRNA) Insider Shannon Thyme Klinger Sells 3,471 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the sale, the insider directly owned 67,468 shares of the company’s stock, valued at $3,373,400. This represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Moderna Stock Performance

Shares of Moderna stock opened at $47.60 on Tuesday. The company has a 50 day moving average of $49.71 and a 200-day moving average of $43.47. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $59.55. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The company has a market cap of $18.89 billion, a PE ratio of -5.84 and a beta of 1.05.

Get Moderna alerts:

Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm had revenue of $389.00 million for the quarter, compared to the consensus estimate of $236.37 million. During the same period last year, the company posted ($2.52) EPS. The business’s revenue was up 260.2% on a year-over-year basis. As a group, equities research analysts forecast that Moderna, Inc. will post -6.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Moderna

Several large investors have recently modified their holdings of MRNA. MUFG Securities EMEA plc acquired a new stake in shares of Moderna during the second quarter worth $28,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Moderna during the fourth quarter worth $31,000. Canton Hathaway LLC acquired a new stake in shares of Moderna during the first quarter worth $31,000. Ameriflex Group Inc. increased its position in shares of Moderna by 3,775.0% during the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock worth $32,000 after buying an additional 1,208 shares during the period. Finally, Cromwell Holdings LLC increased its position in shares of Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after buying an additional 341 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Bank of America increased their price objective on shares of Moderna from $32.00 to $34.00 and gave the company an “underperform” rating in a research note on Monday. Piper Sandler increased their price objective on shares of Moderna from $63.00 to $69.00 and gave the company an “overweight” rating in a research note on Monday, February 23rd. Evercore set a $35.00 price target on shares of Moderna in a research report on Tuesday, February 17th. Jefferies Financial Group set a $37.00 price target on shares of Moderna and gave the company a “hold” rating in a research report on Tuesday, March 3rd. Finally, Royal Bank Of Canada upped their price target on shares of Moderna from $35.00 to $38.00 and gave the company a “sector perform” rating in a research report on Monday, May 4th. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $36.60.

View Our Latest Analysis on MRNA

Moderna Company Profile

(Get Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Read More

• Five stocks we like better than Moderna
• 3 Stocks With Fresh Catalysts to Watch Before the July 4
• Amprius Insiders Are Selling: Should Investors Be Worried?
• A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
• A Market Rotation Toward Quality Will Benefit These 3 ETFs

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.